Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic ...

Preclinical and clinical data demonstrate that neutralizing GDF-15 with visugromab effectively alleviates cancer-induced cachexia, characterized by severe weight and muscle mass loss Patients ...

Preclinical Data with OPN-6602 in Multiple Myeloma Show 100% Tumor Regression in Combination Treatment Studies Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and develop ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...